Rx License-Rx

WU01-01

Transgenic Mouse Model Expressing C217G Uromodulin

Transgenic mouse model expressing a human uromodulin mutant mimicking hereditary human mutant uromodulin caused kidney diseases for testing diagnostics and therapy.

Intelligence Memo

Owner: New York University

Core category: Research Tools

Therapeutic area: Cardiometabolic

Indication: Kidney disease

Modality: Diagnostic / Biomarker

Focus tags: Cardiometabolic

Technology tags: Diagnostic / Biomarker

Mechanism:

Development stage: Preclinical

Patent status: Needs review

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a research tool or translational platform in Cardiometabolic. The near-term value is helping pharma, CROs, or labs make better experimental or patient-selection decisions. The current package appears to be preclinical and is associated with New York University. The practical first use case is Kidney disease. Public description: Transgenic mouse model expressing a human uromodulin mutant mimicking hereditary human mutant uromodulin caused kidney diseases for testing diagnostics and therapy.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

Can sell into pharma before reimbursement: A biomarker or AI tool can create value as trial enrichment, patient stratification, or translational support before becoming a regulated diagnostic.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

IP quality is not yet clear: Patent scope, remaining term, ownership, sponsored-research rights, and freedom to operate need counsel review before deal commitment.

Validation can be harder than the demo: Models and biomarkers need locked datasets, external validation, clinical utility, data rights, and a regulatory/reimbursement plan.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Cardiometabolic wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Roche Diagnostics — Companion diagnostic and translational biomarker fit. Thermo Fisher — Research-tool commercialization and pharma services channels. Illumina / Tempus — Data, sequencing, and clinical decision-support adjacency.

Development Strategy to Increase PoS

First indication: Kidney disease

Study design: Retrospective locked-dataset validation followed by one prospective pharma enrichment pilot.

Key experiments Validate the AI-optimized pivot: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed: Strong enough to test buyer appetite now while validating the cheapest decisive experiment. The most investable version is: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic

Best next experiment: Run the smallest independent study that validates: Package the model or assay with a locked validation dataset, CLIA/service workflow, and one sponsor-ready use case.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.